[443 Pages Report] The global depression treatment market is set to exceed US$ 10.1 Billion in 2022, and expand at a CAGR of 5.2% to reach US$ 16.8 Billion by 2032. According to a recent study, drugs are the leading segment in terms of products and accounted for over 99.4% of the demand share in 2021.
Market Outlook:
| Data Points | Market Insights |
|---|---|
| Depression Treatment Market Value 2021 | US$ 9.7 Billion |
| Market Value 2022 | US$ 10.1 Billion |
| Market Value 2032 | US$ 16.8 Billion |
| CAGR 2022 to 2032 | 5.2% |
| Market Share of Top 5 Countries | 58.9% |
The depression treatment market holds approximately 7.6% of the global behavioral health market worth US$ 128.2 Billion in 2021.
According to World Health Organization (WHO), the prevalence of mental health disorders and conditions is increasing across the globe. There has been a 13% increase in mental health conditions and other depressive disorders in the last decade.
According to the USA Department of Health and Human Services (HHS), in 2020, among adolescents between ages 12 and 17, 17.0% (about 4.1 million population) had a major depressive episode (MDE), and 12% (about 2.9 million people) had MDE with severe impairment.
Several factors such as demographic changes, environmental conditions, and increasing mental stress are resulting in rising mental health disorders. This is improving the growth in the depression treatment market.
According to Future Market Insights (FMI), companies operating in the global depression treatment market are actively seeking to strengthen their position through mergers with established as well as emerging market players. For instance, in November 2020, Mylan completed a merger with Upjohn to form Viatris Company.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
As per FMI, the overall sales of depression treatment expanded at a CAGR of 3.4% from 2012 to 2021 owing to the increase in the prevalence of depression and anxiety disorders. Growth is also contributed to the growing need for antidepressants and therapies to treat mental conditions during the forecast period (2022 to 2032).
Depression treatments during a medical visit are time-consuming, and it is essential that people get treatment on time for depression. If conflicting demands continue to obstruct depression treatment, initiatives must ensure that patients with chronic physical difficulties receive high-quality mental healthcare in primary care.
According to a survey by the American Psychological Association (APA) in 2021, due to the pandemic, mental health issues are continuing to surge. Also, there has been a significant increase in demand for treatments for anxiety and depression compared to the last year.
Further, several new developments in antidepressants in the treatment of depression are being carried out in different drug classes, such as selective serotonin reuptake inhibitors (SSRIs), selective norepinephrine reuptake inhibitors (SNRIs), antipsychotics, and others.
Recently, there has been a major shift in the market for depression disorders and other mental health disorder treatments. Numerous researchers and sponsors are developing novel drugs for the treatment of depression and getting approvals for them in different regions.
For instance, In September 2018, Alembic Pharmaceuticals received US FDA approval for its Desvenlafaxine ER capsules, 25 mg. A slew of these product launches and approvals of novel drugs and therapies in recent years is affecting the depression treatment market positively.
On the back of these aforementioned factors, sales in the depression treatment market are expected to increase at a CAGR of 5.2% from 2022 to 2032 globally.
Governments are trying to increase the funding for mental health services and the treatment of mental illness and depression disorders.
The need for good quality treatments, affordable healthcare policies, funding of government organizations, and interventions of healthcare organizations for mental health disorders treatments are some of the factors boosting the market.
Rising demand for improved brain and mental fitness is opening up new avenues for depression treatments since they improve glucose metabolism in the brain and lower the risk of mental disorders.
Improving healthcare infrastructure and increasing medical expenditure by the governments will support the development of expensive drugs and expensive medical devices. Hence, the demand for depression treatment is expected to further increase over the next few years.
Principal Consultant
The non-availability and the limited number of such well-trained specialists can create an adverse impact on the treatment of patients with depression. Due to these factors, the quality of services can get affected, hampering the growth of the depression treatment market.
The release of generic equivalents to drugs used in the treatment of depression will soon provide the impetus for great total market expansion, resulting in a variety of low-cost prescription options for consumers.
As pharmaceutical companies lose their patent protection, certain products will face generic competition for the first time. The companies that designed the original products will face more competition due to this. Thus, patent expiry problems will hinder the growth of the depression treatment market.
For instance, Lexapro, which is used in the treatment of anxiety and depression, had a patent issue that expired on March 14, 2012.
There is a social stigma associated with depression and other mental diseases. Self-stigmatization makes patients feel ashamed and isolated, and it may hinder them from receiving effective therapy. It could also potentially lead to somatization. difficulty to comprehend for those who have never experienced it can be mistaken as a sign of weakness.
Prevalence of Major Depressive Episodes (MDE) in the USA will Create Growth Prospects for Depression Treatment Market
The USA dominated the North American depression treatment market with a total share of about 92.8% in 2021 and is expected to experience the same growth throughout the forecast period owing to the rise in the prevalence of depressive disorders in the region.
According to the USA Department of Health and Human Services (HHS), in 2020, among adolescents between ages 12 and 17, 17% (about 4.1 million population) had a major depressive episode (MDE), and 12% (about 2.9 million people) had a major depressive episode with severe impairment.
Federal rules on drug launches and the availability of numerous branded formulations have a significant impact on market dynamics.
Increasing Number of Depressive Disorders in Germany will Drive the Demand for Depression Treatment
According to FMI, Germany is set to exhibit a lucrative CAGR of 5.3% in the Europe depression treatment market during the forecast period (2022 to 2032).
As per the Institute for Health Metrics and Evaluation, Germany is having 3.7% of prevalence rate for depression disorders. Hence, the rising prevalence of depressive disorders in Germany will boost the market growth during the forecast period.
Improved Medical Infrastructure in China to Augment the Growth in Depression Treatment Market
China held a 43.4% market share in the East Asia depression treatment market in 2021 and is projected to increase at a CAGR rate of 4.8% during the forecast period. Growth is associated with rising healthcare costs and rapidly improving medical infrastructure is expected to drive the market during the forecast years.
According to Global Health Expenditure Database, the level of per capita health spending in 2020 is expected to be over 5,112 yuan, up from roughly 4,669 yuan the previous year.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Drugs Contribute Over 99.4% of the Depression Treatment Market Sales
Based on products, the drugs segment will project a lucrative growth at a CAGR of 5.2% until 2032, with a market share of around 99.4% in 2021. Drugs are used as the first line of treatment during a depression treatment regime.
As compared to devices, drugs have a higher adoption rate and are cost-effective. TMS devices are commonly employed when other depression therapies have failed. In addition, the administration of drugs, which acts as antidepressants, improves the effectiveness of the treatment of depression without increasing the risk of clinically significant safety events, which makes it the most lucrative in depression treatment.
Rising Prevalence of Major Depression Episodes to Improve Depression Treatment Market Growth
Major depression held a revenue share of 53.5% in 2021 with a CAGR rate of 5.3%. The high market share is because major depression is highly being observed in the population over the world, which includes the symptoms such as anxiety, stress, mental illness, and others.
The high prevalence of major depression in the world is expected to contribute to enhancing market growth from 2022 to 2032.
Hospitals, in terms of distribution channels, led the depression treatment market with a 25.8% market share in 2021. During depression treatment, patients prefer to be admitted to the hospital to seek treatment.
The availability of highly skilled medical professionals that provide better treatment experience also contributed to the high market share during the coming years.
Key players in the depression treatment market are focusing their efforts on acquisitions and expansion to move on with the development of a unique, first-in-class asset for the treatment of cognitive impairment caused by neuropsychiatric and neurodegenerative illnesses.
Given below are a few examples of the key strategies followed by the manufacturers:
| Attribute | Details |
|---|---|
| Forecast Period | 2012 to 2021 |
| Historical Data Available for | 2022 to 2032 |
| Market Analysis | US$ Million for Value |
| Key Regions Covered | North America, Latin America, Europe, South Asia, East Asia, Oceania, and Middle East & Africa |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, Germany, Italy, France, UK, Spain, BENELUX, Russia, China, Japan, South Korea, India, Thailand, Malaysia, Indonesia, Australia, New Zealand, GCC countries, Turkey, South Africa, and North Africa. |
| Key Market Segments Covered | Products, Diseases, Distribution Channels, and Regions |
| Key Companies Profiled |
|
| Pricing | Available upon Request |
The global depression treatment market was worth US$ 9.7 Billion in 2021 and is set to expand 1.7X over the next ten years.
The depression treatment market is expected to reach US$ 16.8 Billion by the end of 2032, with sales revenue expected to register a growth of 5.2% CAGR.
Adoption of different key strategies by market players and mergers and acquisitions by manufacturers are some of the key trends in the depression treatment market.
The USA, Germany, UK, India and China are expected to drive demand for the depression treatment industry.
North America is of the leading depression treatment market, with a market share of 40.3% in 2021 in the global market.
Demand for depression treatment in Europe is expected to register a growth of 5.2% CAGR over the next ten years.
From 2012 to 2021, the market for depression treatment expanded at the rate of 3.4%.
BrainsWay Ltd., Neuronetics, Inc., and Novartis are the Top 3 key players in the depression treatment market.
1. Executive Summary | Depression Treatment Market
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions & Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Innovation / Development Trends
4. Key Success Factors
4.1. Disease Epidemiology, By Region
4.2. Drug Adoption / Usage Analysis
4.3. New Drug Approvals & Launches
4.4. Key Promotional Strategies by Market Players
4.5. Pipeline Analysis
4.6. Regulatory Scenario
4.7. PESTLE Analysis
4.8. Porter’s Analysis
4.9. Value Chain Analysis
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global GDP Growth Outlook
5.1.2. Global Healthcare Market Outlook
5.1.3. Global Mental Health Disorders Market Outlook
5.1.4. Global Pharmaceutical Market Outlook
5.2. Forecast Factors - Relevance & Impact
5.2.1. Top Companies Historical Growth
5.2.2. Product Adoption Rate and Demand
5.2.3. Increasing burden of mental illnesses
5.2.4. Availability of various therapies
5.2.5. COVID-19 impact
5.2.6. Technological Advancements in Equipment
5.2.7. Increasing Demand for Depression Disorders Treatment
5.2.8. New Product Launches
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. COVID19 Crisis Analysis
6.1. Current COVID-19 Statistics and Probable Future Impact
6.2. Current GDP Projection and Probable Impact
6.3. COVID-19 and Impact Analysis
6.4. 2021 Market Scenario
7. Global Market Demand (in Value or Size in US$ Million) Analysis 2012 to 2021 and Forecast, 2022 to 2032
7.1. Historical Market Value (US$ Million) Analysis, 2012 to 2021
7.2. Current and Future Market Value (US$ Million) Projections, 2022 to 2032
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis
8. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, by Product Type
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Million) Analysis By Product Type, 2012 to 2021
8.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Product Type, 2022 to 2032
8.3.1. Drugs
8.3.1.1. Selective Serotonin Reuptake Inhibitors (SSRIs)
8.3.1.1.1. Citalopram
8.3.1.1.2. Escitalopram
8.3.1.1.3. Fluoxetine
8.3.1.1.4. Fluvoxamine
8.3.1.1.5. Paroxetine
8.3.1.1.6. Sertraline
8.3.1.2. Selective Norepinephrine Reuptake Inhibitors (SNRIs)
8.3.1.2.1. Desvenlafaxine succinate
8.3.1.2.2. Duloxetine
8.3.1.2.3. Levomilnacipran
8.3.1.2.4. Venlafaxine
8.3.1.3. Bupropion
8.3.1.4. Mirtazapine
8.3.1.5. Monoamine oxidase inhibitors (MAOIs)
8.3.1.5.1. Phenelzine
8.3.1.5.2. Tranylcypromine
8.3.1.6. Antipsychotics
8.3.1.6.1. Lithium carbonate
8.3.1.6.2. Aripiprazole
8.3.1.6.3. Brexipiprazole
8.3.1.6.4. Quetiapine
8.3.1.7. Trazodone
8.3.1.8. Others
8.3.2. TMS Devices
8.3.2.1. rTMS Devices
8.3.2.2. dTMS Devices
8.4. Market Attractiveness Analysis By Disease Type
9. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, by Disease Type
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Million) Analysis By Disease Type, 2012 to 2021
9.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Disease Type, 2022 to 2032
9.3.1. Major Depression
9.3.2. Persistent Depressive Disorder
9.3.3. Bipolar Disorder
9.3.4. Seasonal Affective Disorder (SAD)
9.3.5. Postpartum Depression
9.3.6. Premenstrual Dysphoric Disorder (PDD)
9.3.7. Situational Depression
9.3.8. Atypical Depression
9.3.9. Treatment-Resistant Depression
9.4. Market Attractiveness Analysis By Disease Type
10. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, by Distribution Channel
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Million) Analysis By Distribution Channel, 2012 to 2021
10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Distribution Channel 2022 to 2032
10.3.1. Hospitals
10.3.2. Retail Pharmacies
10.3.3. Drug Stores
10.3.4. e-commerce
10.3.5. Specialty Clinics
10.4. Market Attractiveness Analysis By Distribution Channel
11. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, by Region
11.1. Introduction
11.2. Historical Market Size (US$ Million) Analysis, By Region, 2012 to 2021
11.3. Current Market Size (US$ Million) Analysis and Forecast By Region, 2022 to 2032
11.3.1. North America
11.3.2. Latin America
11.3.3. Europe
11.3.4. East Asia
11.3.5. South Asia
11.3.6. Oceania
11.3.7. Middle East and Africa (MEA)
11.4. Market Attractiveness Analysis By Region
12. North America Market Analysis 2012 to 2021 and Forecast 2022 to 2032
12.1. Introduction
12.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2012 to 2021
12.3. Market Size (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
12.3.1. By Country
12.3.1.1. United States of America
12.3.1.2. Canada
12.3.2. By Product Type
12.3.3. By Disease Type
12.3.4. By Distribution Channel
12.4. Market Attractiveness Analysis
12.4.1. By Country
12.4.2. By Product Type
12.4.3. By Disease Type
12.4.4. By Distribution Channel
12.5. Market Trends
12.6. Key Market Participants - Intensity Mapping
12.7. Drivers and Restraints - Impact Analysis
12.8. Country-Level Analysis & Forecast
12.8.1. USA Market
12.8.1.1. Introduction
12.8.1.2. Market Analysis and Forecast by Market Taxonomy
12.8.1.2.1. By Product Type
12.8.1.2.2. By Disease Type
12.8.1.2.3. By Distribution Channel
12.8.2. Canada Market
12.8.2.1. Introduction
12.8.2.2. Market Analysis and Forecast by Market Taxonomy
12.8.2.2.1. By Product Type
12.8.2.2.2. By Disease Type
12.8.2.2.3. By Distribution Channel
13. Latin America Market Analysis 2012 to 2021 and Forecast 2022 to 2032
13.1. Introduction
13.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2012 to 2021
13.3. Market Size (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
13.3.1. By Country
13.3.1.1. Brazil
13.3.1.2. Mexico
13.3.1.3. Argentina
13.3.1.4. Rest of Latin America
13.3.2. By Product Type
13.3.3. By Disease Type
13.3.4. By Distribution Channel
13.4. Market Attractiveness Analysis
13.4.1. By Country
13.4.2. By Product Type
13.4.3. By Disease Type
13.4.4. By Distribution Channel
13.5. Market Trends
13.6. Key Market Participants - Intensity Mapping
13.7. Drivers and Restraints - Impact Analysis
13.8. Country-Level Analysis & Forecast
13.8.1. Brazil Market
13.8.1.1. Introduction
13.8.1.2. Market Analysis and Forecast by Market Taxonomy
13.8.1.2.1. By Product Type
13.8.1.2.2. By Disease Type
13.8.1.2.3. By Distribution Channel
13.8.2. Mexico Market
13.8.2.1. Introduction
13.8.2.2. Market Analysis and Forecast by Market Taxonomy
13.8.2.2.1. By Product Type
13.8.2.2.2. By Disease Type
13.8.2.2.3. By Distribution Channel
13.8.3. Argentina Market
13.8.3.1. Introduction
13.8.3.2. Market Analysis and Forecast by Market Taxonomy
13.8.3.2.1. By Product Type
13.8.3.2.2. By Disease Type
13.8.3.2.3. By Distribution Channel
14. Europe Market Analysis 2012 to 2021 and Forecast 2022 to 2032
14.1. Introduction
14.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2012 to 2021
14.3. Market Size (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
14.3.1. By Country
14.3.1.1. United Kingdom
14.3.1.2. Germany
14.3.1.3. Italy
14.3.1.4. France
14.3.1.5. Spain
14.3.1.6. Russia
14.3.1.7. BENELUX
14.3.1.8. Rest of Europe
14.3.2. By Product Type
14.3.3. By Disease Type
14.3.4. By Distribution Channel
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By Product Type
14.4.3. By Disease Type
14.4.4. By Distribution Channel
14.5. Market Trends
14.6. Key Market Participants - Intensity Mapping
14.7. Drivers and Restraints - Impact Analysis
14.8. Country-Level Analysis & Forecast
14.8.1. UK Market
14.8.1.1. Introduction
14.8.1.2. Market Analysis and Forecast by Market Taxonomy
14.8.1.2.1. By Product Type
14.8.1.2.2. By Disease Type
14.8.1.2.3. By Distribution Channel
14.8.2. Germany Market
14.8.2.1. Introduction
14.8.2.2. Market Analysis and Forecast by Market Taxonomy
14.8.2.2.1. By Product Type
14.8.2.2.2. By Disease Type
14.8.2.2.3. By Distribution Channel
14.8.3. Italy Market
14.8.3.1. Introduction
14.8.3.2. Market Analysis and Forecast by Market Taxonomy
14.8.3.2.1. By Product Type
14.8.3.2.2. By Disease Type
14.8.3.2.3. By Distribution Channel
14.8.4. France Market
14.8.4.1. Introduction
14.8.4.2. Market Analysis and Forecast by Market Taxonomy
14.8.4.2.1. By Product Type
14.8.4.2.2. By Disease Type
14.8.4.2.3. By Distribution Channel
14.8.5. Spain Market
14.8.5.1. Introduction
14.8.5.2. Market Analysis and Forecast by Market Taxonomy
14.8.5.2.1. By Product Type
14.8.5.2.2. By Disease Type
14.8.5.2.3. By Distribution Channel
14.8.6. Russia Market
14.8.6.1. Introduction
14.8.6.2. Market Analysis and Forecast by Market Taxonomy
14.8.6.2.1. By Product Type
14.8.6.2.2. By Disease Type
14.8.6.2.3. By Distribution Channel
14.8.7. BENELUX Market
14.8.7.1. Introduction
14.8.7.2. Market Analysis and Forecast by Market Taxonomy
14.8.7.2.1. By Disease Type
14.8.7.2.2. By Product Type
14.8.7.2.3. By Distribution Channel
15. South Asia Market Analysis 2012 to 2021 and Forecast 2022 to 2032
15.1. Introduction
15.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2012 to 2021
15.3. Market Size (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
15.3.1. By Country
15.3.1.1. India
15.3.1.2. Thailand
15.3.1.3. Indonesia
15.3.1.4. Malaysia
15.3.1.5. Rest of South Asia
15.3.2. By Product Type
15.3.3. By Disease Type
15.3.4. By Distribution Channel
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Product Type
15.4.3. By Disease Type
15.4.4. By Distribution Channel
15.5. Market Trends
15.6. Key Market Participants - Intensity Mapping
15.7. Drivers and Restraints - Impact Analysis
15.8. Country-Level Analysis & Forecast
15.8.1. India Market
15.8.1.1. Introduction
15.8.1.2. Market Analysis and Forecast by Market Taxonomy
15.8.1.2.1. By Product Type
15.8.1.2.2. By Disease Type
15.8.1.2.3. By Distribution Channel
15.8.2. Thailand Market
15.8.2.1. Introduction
15.8.2.2. Market Analysis and Forecast by Market Taxonomy
15.8.2.2.1. By Product Type
15.8.2.2.2. By Disease Type
15.8.2.2.3. By Distribution Channel
15.8.3. Indonesia Market
15.8.3.1. Introduction
15.8.3.2. Market Analysis and Forecast by Market Taxonomy
15.8.3.2.1. By Product Type
15.8.3.2.2. By Disease Type
15.8.3.2.3. By Distribution Channel
15.8.4. Malaysia Market
15.8.4.1. Introduction
15.8.4.2. Market Analysis and Forecast by Market Taxonomy
15.8.4.2.1. By Product Type
15.8.4.2.2. By Disease Type
15.8.4.2.3. By Distribution Channel
16. East Asia Market Analysis 2012 to 2021 and Forecast 2022 to 2032
16.1. Introduction
16.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2012 to 2021
16.3. Market Size (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
16.3.1. By Country
16.3.1.1. China
16.3.1.2. Japan
16.3.1.3. South Korea
16.3.2. By Product Type
16.3.3. By Disease Type
16.3.4. By Distribution Channel
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Product Type
16.4.3. By Disease Type
16.4.4. By Distribution Channel
16.5. Market Trends
16.6. Key Market Participants - Intensity Mapping
16.7. Drivers and Restraints - Impact Analysis
16.8. Country-Level Analysis & Forecast
16.8.1. China Market
16.8.1.1. Introduction
16.8.1.2. Market Analysis and Forecast by Market Taxonomy
16.8.1.2.1. By Product Type
16.8.1.2.2. By Disease Type
16.8.1.2.3. By Distribution Channel
16.8.2. Japan Market
16.8.2.1. Introduction
16.8.2.2. Market Analysis and Forecast by Market Taxonomy
16.8.2.2.1. By Product Type
16.8.2.2.2. By Disease Type
16.8.2.2.3. By Distribution Channel
16.8.3. South Korea Market
16.8.3.1. Introduction
16.8.3.2. Market Analysis and Forecast by Market Taxonomy
16.8.3.2.1. By Product Type
16.8.3.2.2. By Disease Type
16.8.3.2.3. By Distribution Channel
17. Oceania Market Analysis 2012 to 2021 and Forecast 2022 to 2032
17.1. Introduction
17.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2012 to 2021
17.3. Market Size (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
17.3.1. By Country
17.3.1.1. Australia
17.3.1.2. New Zealand
17.3.2. By Product Type
17.3.3. By Disease Type
17.3.4. By Distribution Channel
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Product Type
17.4.3. By Disease Type
17.4.4. By Distribution Channel
17.5. Market Trends
17.6. Key Market Participants - Intensity Mapping
17.7. Drivers and Restraints - Impact Analysis
17.8. Country-Level Analysis & Forecast
17.8.1. Australia Market
17.8.1.1. Introduction
17.8.1.2. Market Analysis and Forecast by Market Taxonomy
17.8.1.2.1. By Product Type
17.8.1.2.2. By Disease Type
17.8.1.2.3. By Distribution Channel
17.8.2. New Zealand Market
17.8.2.1. Introduction
17.8.2.2. Market Analysis and Forecast by Market Taxonomy
17.8.2.2.1. By Product Type
17.8.2.2.2. By Disease Type
17.8.2.2.3. By Distribution Channel
18. Middle East and Africa (MEA) Market Analysis 2012 to 2021 and Forecast 2022 to 2032
18.1. Introduction
18.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2012 to 2021
18.3. Market Size (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
18.3.1. By Country
18.3.1.1. Turkey
18.3.1.2. GCC Countries
18.3.1.3. North Africa
18.3.1.4. South Africa
18.3.1.5. Rest of Middle East and Africa
18.3.2. By Product Type
18.3.3. By Disease Type
18.3.4. By Distribution Channel
18.4. Market Attractiveness Analysis
18.4.1. By Country
18.4.2. By Product Type
18.4.3. By Disease Type
18.4.4. By Distribution Channel
18.5. Market Trends
18.6. Key Market Participants - Intensity Mapping
18.7. Drivers and Restraints - Impact Analysis
18.8. Country-Level Analysis & Forecast
18.8.1. Turkey Market
18.8.1.1. Introduction
18.8.1.2. Market Analysis and Forecast by Market Taxonomy
18.8.1.2.1. By Product Type
18.8.1.2.2. By Disease Type
18.8.1.2.3. By Distribution Channel
18.8.2. GCC Countries Market
18.8.2.1. Introduction
18.8.2.2. Market Analysis and Forecast by Market Taxonomy
18.8.2.2.1. By Product Type
18.8.2.2.2. By Disease Type
18.8.2.2.3. By Distribution Channel
18.8.3. North Africa Market
18.8.3.1. Introduction
18.8.3.2. Market Analysis and Forecast by Market Taxonomy
18.8.3.2.1. By Product Type
18.8.3.2.2. By Disease Type
18.8.3.2.3. By Distribution Channel
18.8.4. South Africa Market
18.8.4.1. Introduction
18.8.4.2. Market Analysis and Forecast by Market Taxonomy
18.8.4.2.1. By Product Type
18.8.4.2.2. By Disease Type
18.8.4.2.3. By Distribution Channel
19. Market Structure Analysis
19.1. Market Analysis by Tier of Companies
19.2. Market Share Analysis of Top Players
19.3. Market Presence Analysis
20. Competition Analysis
20.1. Competition Dashboard
20.2. Technology Foot-Print, By Competition
20.3. Competition Benchmarking
20.4. Competition Deep Dive
20.4.1. Viatris (Mylan Pharmaceuticals Inc.)
20.4.1.1. Overview
20.4.1.2. Product Portfolio
20.4.1.3. Key Financials
20.4.1.4. SWOT Analysis
20.4.1.5. Sales Footprint
20.4.1.6. Strategy Overview
20.4.1.7. Key Developments
20.4.2. Sunovian Pharmaceuticals
20.4.2.1. Overview
20.4.2.2. Product Portfolio
20.4.2.3. Key Financials
20.4.2.4. SWOT Analysis
20.4.2.5. Sales Footprint
20.4.2.6. Strategy Overview
20.4.2.7. Key Developments
20.4.3. AbbVie Inc (Allergan, Inc.)
20.4.3.1. Overview
20.4.3.2. Product Portfolio
20.4.3.3. Key Financials
20.4.3.4. SWOT Analysis
20.4.3.5. Sales Footprint
20.4.3.6. Strategy Overview
20.4.3.7. Key Developments
20.4.4. Jubilant Generics Limited
20.4.4.1. Overview
20.4.4.2. Product Portfolio
20.4.4.3. Key Financials
20.4.4.4. SWOT Analysis
20.4.4.5. Sales Footprint
20.4.4.6. Strategy Overview
20.4.4.7. Key Developments
20.4.5. Sanis Health Inc
20.4.5.1. Overview
20.4.5.2. Product Portfolio
20.4.5.3. Key Financials
20.4.5.4. SWOT Analysis
20.4.5.5. Sales Footprint
20.4.5.6. Strategy Overview
20.4.5.7. Key Developments
20.4.6. Abbott Laboratories
20.4.6.1. Overview
20.4.6.2. Product Portfolio
20.4.6.3. Key Financials
20.4.6.4. SWOT Analysis
20.4.6.5. Sales Footprint
20.4.6.6. Strategy Overview
20.4.6.7. Key Developments
20.4.7. Aurobindo Pharma
20.4.7.1. Overview
20.4.7.2. Product Portfolio
20.4.7.3. Key Financials
20.4.7.4. SWOT Analysis
20.4.7.5. Sales Footprint
20.4.7.6. Strategy Overview
20.4.7.7. Key Developments
20.4.8. Torrent Pharmaceuticals
20.4.8.1. Overview
20.4.8.2. Product Portfolio
20.4.8.3. Key Financials
20.4.8.4. SWOT Analysis
20.4.8.5. Sales Footprint
20.4.8.6. Strategy Overview
20.4.8.7. Key Developments
20.4.9. Teva Pharmaceuticals
20.4.9.1. Overview
20.4.9.2. Product Portfolio
20.4.9.3. Key Financials
20.4.9.4. SWOT Analysis
20.4.9.5. Sales Footprint
20.4.9.6. Strategy Overview
20.4.9.7. Key Developments
20.4.10. Sun Pharmaceuticals
20.4.10.1. Overview
20.4.10.2. Product Portfolio
20.4.10.3. Key Financials
20.4.10.4. SWOT Analysis
20.4.10.5. Sales Footprint
20.4.10.6. Strategy Overview
20.4.10.7. Key Developments
20.4.11. (Apotex Holdings, Inc.) Apotex Corporation
20.4.11.1. Overview
20.4.11.2. Product Portfolio
20.4.11.3. Key Financials
20.4.11.4. SWOT Analysis
20.4.11.5. Sales Footprint
20.4.11.6. Strategy Overview
20.4.11.7. Key Developments
20.4.12. Alembic Pharmaceuticals Limited
20.4.12.1. Overview
20.4.12.2. Product Portfolio
20.4.12.3. Key Financials
20.4.12.4. SWOT Analysis
20.4.12.5. Sales Footprint
20.4.12.6. Strategy Overview
20.4.12.7. Key Developments
20.4.13. Pfizer Inc
20.4.13.1. Overview
20.4.13.2. Product Portfolio
20.4.13.3. Key Financials
20.4.13.4. SWOT Analysis
20.4.13.5. Sales Footprint
20.4.13.6. Strategy Overview
20.4.13.7. Key Developments
20.4.14. Cardinal Health
20.4.14.1. Overview
20.4.14.2. Product Portfolio
20.4.14.3. Key Financials
20.4.14.4. SWOT Analysis
20.4.14.5. Sales Footprint
20.4.14.6. Strategy Overview
20.4.14.7. Key Developments
20.4.15. Hikma Pharmaceuticals
20.4.15.1. Overview
20.4.15.2. Product Portfolio
20.4.15.3. Key Financials
20.4.15.4. SWOT Analysis
20.4.15.5. Sales Footprint
20.4.15.6. Strategy Overview
20.4.15.7. Key Developments
20.4.16. Zydus Lifesciences (Cadila)
20.4.16.1. Overview
20.4.16.2. Product Portfolio
20.4.16.3. Key Financials
20.4.16.4. SWOT Analysis
20.4.16.5. Sales Footprint
20.4.16.6. Strategy Overview
20.4.16.7. Key Developments
20.4.17. Cipla Ltd
20.4.17.1. Overview
20.4.17.2. Product Portfolio
20.4.17.3. Key Financials
20.4.17.4. SWOT Analysis
20.4.17.5. Sales Footprint
20.4.17.6. Strategy Overview
20.4.17.7. Key Developments
20.4.18. Dr. Reddy's Laboratories
20.4.18.1. Overview
20.4.18.2. Product Portfolio
20.4.18.3. Key Financials
20.4.18.4. SWOT Analysis
20.4.18.5. Sales Footprint
20.4.18.6. Strategy Overview
20.4.18.7. Key Developments
20.4.19. Merck & Co.
20.4.19.1. Overview
20.4.19.2. Product Portfolio
20.4.19.3. Key Financials
20.4.19.4. SWOT Analysis
20.4.19.5. Sales Footprint
20.4.19.6. Strategy Overview
20.4.19.7. Key Developments
20.4.20. Eli Lily & Co
20.4.20.1. Overview
20.4.20.2. Product Portfolio
20.4.20.3. Key Financials
20.4.20.4. SWOT Analysis
20.4.20.5. Sales Footprint
20.4.20.6. Strategy Overview
20.4.20.7. Key Developments
20.4.21. GlaxoSmithKline
20.4.21.1. Overview
20.4.21.2. Product Portfolio
20.4.21.3. Key Financials
20.4.21.4. SWOT Analysis
20.4.21.5. Sales Footprint
20.4.21.6. Strategy Overview
20.4.21.7. Key Developments
20.4.22. Takeda Pharmaceuticals
20.4.22.1. Overview
20.4.22.2. Product Portfolio
20.4.22.3. Key Financials
20.4.22.4. SWOT Analysis
20.4.22.5. Sales Footprint
20.4.22.6. Strategy Overview
20.4.22.7. Key Developments
20.4.23. BrainsWay Ltd.
20.4.23.1. Overview
20.4.23.2. Product Portfolio
20.4.23.3. Key Financials
20.4.23.4. SWOT Analysis
20.4.23.5. Sales Footprint
20.4.23.6. Strategy Overview
20.4.23.7. Key Developments
20.4.24. Nexstim Plc
20.4.24.1. Overview
20.4.24.2. Product Portfolio
20.4.24.3. Key Financials
20.4.24.4. SWOT Analysis
20.4.24.5. Sales Footprint
20.4.24.6. Strategy Overview
20.4.24.7. Key Developments
20.4.25. Magstim Ltd.
20.4.25.1. Overview
20.4.25.2. Product Portfolio
20.4.25.3. Key Financials
20.4.25.4. SWOT Analysis
20.4.25.5. Sales Footprint
20.4.25.6. Strategy Overview
20.4.25.7. Key Developments
20.4.26. Neuronetics, Inc.
20.4.26.1. Overview
20.4.26.2. Product Portfolio
20.4.26.3. Key Financials
20.4.26.4. SWOT Analysis
20.4.26.5. Sales Footprint
20.4.26.6. Strategy Overview
20.4.26.7. Key Developments
20.4.27. Salience TMS Neuro Solutions
20.4.27.1. Overview
20.4.27.2. Product Portfolio
20.4.27.3. Key Financials
20.4.27.4. SWOT Analysis
20.4.27.5. Sales Footprint
20.4.27.6. Strategy Overview
20.4.27.7. Key Developments
20.4.28. MagVenture
20.4.28.1. Overview
20.4.28.2. Product Portfolio
20.4.28.3. Key Financials
20.4.28.4. SWOT Analysis
20.4.28.5. Sales Footprint
20.4.28.6. Strategy Overview
20.4.28.7. Key Developments
20.4.29. MAG & More GmbH
20.4.29.1. Overview
20.4.29.2. Product Portfolio
20.4.29.3. Key Financials
20.4.29.4. SWOT Analysis
20.4.29.5. Sales Footprint
20.4.29.6. Strategy Overview
20.4.29.7. Key Developments
20.4.30. Neurosoft, Ltd.
20.4.30.1. Overview
20.4.30.2. Product Portfolio
20.4.30.3. Key Financials
20.4.30.4. SWOT Analysis
20.4.30.5. Sales Footprint
20.4.30.6. Strategy Overview
20.4.30.7. Key Developments
21. Assumptions and Acronyms Used
22. Research Methodology
Explore Healthcare Insights
View Reports
Depression Treatment Market
